Exelixis (EXEL) Free Cash Flow (2010 - 2026)
Exelixis (EXEL) recorded quarterly Free Cash Flow of $250.3 million in Q2 2026, down 24.68% quarter-over-quarter from $332.4 million in Q1 2026, and up 20.07% on a YoY basis from $208.5 million in Q2 2025.
Exelixis (EXEL) Free Cash Flow (2010 - 2026) Analysis & Trends
Exelixis' Free Cash Flow history runs 17 years deep, the most recent figure standing at $250.3 million for Q2 2026.
- In Q2 2026, Free Cash Flow rose 20.07% year-over-year to $250.3 million; the TTM figure through Apr 2026 stood at $917.7 million (up 11.79% YoY), while the FY2026 annual figure was $875.8 million, up 30.42% from the prior year.
- Free Cash Flow was $250.3 million for Q2 2026 at Exelixis, down from $332.4 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $332.4 million in Q1 2026 to a low of -$2.6 million in Q4 2023.
- Historically, Free Cash Flow has averaged $142.7 million across 5 years, with a median of $113.0 million in 2024.
- The sharpest annual moves came in 2023 and 2025: Free Cash Flow plunged 104.01% in 2023, then jumped 9315.52% in 2025.
- A 5-year view of Free Cash Flow shows it stood at $64.0 million in 2022, then slumped by 104.01% to -$2.6 million in 2023, then surged by 10362.91% to $263.1 million in 2024, then climbed by 9.77% to $288.8 million in 2025, then decreased by 13.33% to $250.3 million in 2026.
- The last three Free Cash Flow figures came in at $250.3 million (Q2 2026), $332.4 million (Q1 2026), and $288.8 million (Q4 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 63,220.27 |
| 10 | Exelixis | 13.71 Bn | 12.93 Bn | 590.86 Mn | 250.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 250.34 Mn |
| Apr 3, 2026 | 250.34 Mn |
| Jan 2, 2026 | 332.36 Mn |
| Jan 2, 2026 | 332.36 Mn |
| Oct 3, 2025 | 288.84 Mn |
| Oct 3, 2025 | 288.84 Mn |
| Jul 4, 2025 | 46.16 Mn |
| Jul 4, 2025 | 46.16 Mn |
| Apr 4, 2025 | 208.49 Mn |
| Apr 4, 2025 | 208.49 Mn |
| Jan 3, 2025 | 236.29 Mn |
| Jan 3, 2025 | 236.29 Mn |
| Sep 27, 2024 | 263.14 Mn |
| Sep 27, 2024 | 263.14 Mn |
| Jun 28, 2024 | 112.98 Mn |
| Jun 28, 2024 | 112.98 Mn |
| Mar 29, 2024 | 59.13 Mn |
| Mar 29, 2024 | 59.13 Mn |
| Dec 29, 2023 | -2.56 Mn |
| Dec 29, 2023 | -2.56 Mn |